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2. Background
•HEAT is being conducted in GP practices across the whole of the
UK
•HEAT is important medically because aspirin is so widely used,
and methodologically as, if successful, it will demonstrate that
large-scale studies of important clinical outcomes can be
conducted at a fraction of the cost of those conducted by industry
•The primary endpoint of the study is the rate of hospitalisation due
to definite or probable peptic ulcer bleeding
•The study will end when 87 adjudicated events have occurred
For further details, please contact: Jen Dumbleton (Trial Manager), 
0115 823 1053  jennifer.dumbleton@nottingham.ac.uk
5. Conclusion
The trial methodology has shown that recruitment of large numbers 
of participants from primary care is attainable, with the assistance 
of the NIHR Clinical Research Network, and could be applied to 
other outcomes studies at relatively low cost. 
Last year, there were almost 17,000 hospital admissions for gastric 
ulcers [2] and more than 1,850 recorded deaths [3] for gastric and 
duodenal ulcers. If successful, the study will help to reduce NHS 
costs and improve health outcomes by reducing hospital 
admissions, increasing patient safety and preventing premature 
deaths.
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1. Introduction
The Helicobacter Eradication Aspirin Trial (HEAT) is a multicentre, double blind, randomised controlled trial investigating whether Helicobacter pylori eradication reduces the incidence of hospitalisation for peptic ulcer bleeding [1].
3. Methods
• Participants are aged over 60, taking low dose aspirin for at least four months at the time of recruitment; all participants were recruited from primary care.
• Participants testing positive for H. pylori were randomised to receive one week active trial treatment (lansoprazole 30mg, clarithromycin 500mg and metronidazole
400mg twice daily) or placebo
• Participants are followed up using a bespoke web-based trial management system that communicates directly with HEAT Toolkit software downloaded at
contributing GP practices, which issues electronic queries searching follow-up criteria
• Events are tracked by accumulating information from electronic searches of GP databases via the HEAT toolkit, patient contact, review of national Hospital Episode
Statistics secondary care admission and ONS mortality data
4. Results
• Recruitment to the trial started in 2012 and completed in 2017;
follow-up is endpoint driven and is ongoing
• HEAT is the largest CRN CTIMP trial, with 188,428 invitation
letters sent from 1,208 practices
• A total of 37,247 positive responses were received, representing
a 20% response rate
• 30,025 participants were consented to the study of whom 5,356
H. pylori positive participants were randomised.
• The mean age at randomisation for the H pylori-positive
participants was 73.6 ± 7.0 (SD) years, and 73.8% of participants
were male. Only 7.2% of participants were smokers although
52.9% were ex-smokers
• Recruitment figures for English participants were analysed with
respect to Multiple Deprivation Indices (MDI) [4] of the GP
practices. MDI=1 represents the 10% most deprived and MDI=10
is the 10% least deprived
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Figure 1: Participant recruitment by CRN region
Figures show the mean ± SD of percentages calculated for each 
contributing GP practice in the respective CRN regions
Fig 1a shows HEAT participants consented in each CRN region 
expressed as a percentage of the number of invitation letters sent 
out by each contributing practice in each region
Fig 1b shows randomised participants (ie H pylori positive) in each 
CRN region expressed as a percentage of the number of consented 
participants. The percent of H. pylori positive participants varied 
from 13% to 39% throughout the country
The NIHR CRN in England and the Health Boards in Wales, 
Scotland and Northern Ireland have played a large role in facilitating 
the trial and have enabled us to recruit all over the UK
Figure 2: Participant recruitment in England with respect to the 
Multiple Deprivation Index of their respective GP practices
Figures show the mean ± SD of percentages calculated for each 
contributing GP practice in the respective MDI category
Fig 2a shows participants attending HEAT consent clinics 
expressed as a percentage of the number of invitation letters sent
Fig 2b shows HEAT randomised participants expressed as a 
percentage of the number of participants attending consent clinics
The percentage of participants attending consent visits with respect 
to the number of invitation letters sent out by the practices 
increased with a lesser amount of deprivation (Fig 2a), but the 
percentage of randomised participants decreased (Fig 2b)
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